Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): A Southwest Oncology Group study

Thomas P Miller, J. K. Weick, P. N. Grozea, D. A. Carlin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Sixty-three previously untreated patients with metastatic non- small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi). FEMi was repeated at 3-week intervals for three treatment courses and thereafter at 6-week intervals until disease progression. Major objective responses were seen in 13 of the 63 patients (21%). Minor responses were seen in an additional 12 patients (19%). The median survival for all patients was 23 weeks and for responding patients was 38 weeks. The pretreatment performance status had a significant effect on both the response rate and survival time. Patients having an initial Karnofsky performance score ≥70% had a 54% response rate, with a medium survival of 42 weeks for responding patients. FEMi was well- tolerated: 18 patients (29%) did not have any side effects and only five (8%) experienced vomiting.

Original languageEnglish (US)
Pages (from-to)553-556
Number of pages4
JournalCancer Treatment Reports
Volume66
Issue number3
StatePublished - 1982
Externally publishedYes

Fingerprint

Vindesine
Large Cell Carcinoma
Fluorouracil
Adenocarcinoma
Carcinoma
Lung
Mitomycin
mitomycin A
Survival
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Vomiting
Disease Progression
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi) : A Southwest Oncology Group study. / Miller, Thomas P; Weick, J. K.; Grozea, P. N.; Carlin, D. A.

In: Cancer Treatment Reports, Vol. 66, No. 3, 1982, p. 553-556.

Research output: Contribution to journalArticle

@article{918c382394564b03af74268008d4cdd9,
title = "Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): A Southwest Oncology Group study",
abstract = "Sixty-three previously untreated patients with metastatic non- small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi). FEMi was repeated at 3-week intervals for three treatment courses and thereafter at 6-week intervals until disease progression. Major objective responses were seen in 13 of the 63 patients (21{\%}). Minor responses were seen in an additional 12 patients (19{\%}). The median survival for all patients was 23 weeks and for responding patients was 38 weeks. The pretreatment performance status had a significant effect on both the response rate and survival time. Patients having an initial Karnofsky performance score ≥70{\%} had a 54{\%} response rate, with a medium survival of 42 weeks for responding patients. FEMi was well- tolerated: 18 patients (29{\%}) did not have any side effects and only five (8{\%}) experienced vomiting.",
author = "Miller, {Thomas P} and Weick, {J. K.} and Grozea, {P. N.} and Carlin, {D. A.}",
year = "1982",
language = "English (US)",
volume = "66",
pages = "553--556",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi)

T2 - A Southwest Oncology Group study

AU - Miller, Thomas P

AU - Weick, J. K.

AU - Grozea, P. N.

AU - Carlin, D. A.

PY - 1982

Y1 - 1982

N2 - Sixty-three previously untreated patients with metastatic non- small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi). FEMi was repeated at 3-week intervals for three treatment courses and thereafter at 6-week intervals until disease progression. Major objective responses were seen in 13 of the 63 patients (21%). Minor responses were seen in an additional 12 patients (19%). The median survival for all patients was 23 weeks and for responding patients was 38 weeks. The pretreatment performance status had a significant effect on both the response rate and survival time. Patients having an initial Karnofsky performance score ≥70% had a 54% response rate, with a medium survival of 42 weeks for responding patients. FEMi was well- tolerated: 18 patients (29%) did not have any side effects and only five (8%) experienced vomiting.

AB - Sixty-three previously untreated patients with metastatic non- small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi). FEMi was repeated at 3-week intervals for three treatment courses and thereafter at 6-week intervals until disease progression. Major objective responses were seen in 13 of the 63 patients (21%). Minor responses were seen in an additional 12 patients (19%). The median survival for all patients was 23 weeks and for responding patients was 38 weeks. The pretreatment performance status had a significant effect on both the response rate and survival time. Patients having an initial Karnofsky performance score ≥70% had a 54% response rate, with a medium survival of 42 weeks for responding patients. FEMi was well- tolerated: 18 patients (29%) did not have any side effects and only five (8%) experienced vomiting.

UR - http://www.scopus.com/inward/record.url?scp=0019981654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019981654&partnerID=8YFLogxK

M3 - Article

C2 - 6277487

AN - SCOPUS:0019981654

VL - 66

SP - 553

EP - 556

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -